Be the first person to write a business review for Cardium Therapeutics, Inc.

CEDRA is a contract research organization, deep in the heart of Texas. CEDRA conducts phase I-IV clinical drug trials at its facilities in Austin and San Antonio, including general pharmacodynamics (what a drug does to a live human body) and pharmacokinetics (what a live human body does to a drug). The company also performs bioequivalency studies for generic pharmaceutical makers. It has experience in testing drugs ranging from allergy medicines to pain management and Parkinson's drugs. Its research customers include pharmaceutical and biotechnology drug makers, as well as the federal government. CEDRA is a division of Worldwide Clinical Trials.

CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is immunotherapy, incorporating both active and passive immune activity.

Celgene Corporation company was founded in 1980 and is headquartered in Summit, New Jersey. Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum.Celgene Corporation company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer.

Celgene Signal Research (also known as Celgene Research San Diego) wouldn't want it any other way. This Celgene division works to identify potential drug candidates with a focus on regulating genes and the production of disease-causing proteins. Much of its work has been to identify and map certain kinase and ligase proteins, which future Celgene drugs are then designed to inhibit. Celgene Signal Research's drug discovery programs target inflammatory diseases, as well as cancers such as leukemia.

Cell Therapeutics, Inc. company was founded in 1991 and is headquartered in Seattle, Washington. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.